Printer Friendly

RUSSIA APPROVES FIST ONCE-A-DAY QUINOLONE FOR ANTI-INFECTIVE USE

 RUSSIA APPROVES FIST ONCE-A-DAY QUINOLONE FOR ANTI-INFECTIVE USE
 CHICAGO, July 22 /PRNewswire/ -- Searle's Maxaquin(R) (lomefloxacin HCI), the first once-a-day, quinolone anitbacterial agent, has been approved for use in Russia.
 The broad-spectrum antimicrobial drug was approved for use in treating complicated and uncomplicated urinary tract infections (UTIs), lower-respiratory-tract infections, and infections of the skin and skin structures.
 "The approval of Maxaquin by the Russian Ministry of Health indicates that this drug -- the first one-tablet, once-a-day, broad- spectrum quinolone -- fills an important gap in the anti-infective market," says Ronald Goode, PhD, president of Searle International Operations. "We are pleased that Searle has been able to fill that need, and are confident it will improve the care available to Russian citizens."
 Maxaquin was approved in the United States in February and in the United Kingdom in June. In Japan, where it has been available since 1990, Maxaquin has a current sales volume of more than $100 million per year. Other countries that have approved the use of Maxaquin are Ireland, Brazil, Mexico, Italy, Portugal and Venezuala. (Specific approval indications and conditions may vary by country.) Applications are pending in many other countries.
 Like other quinolones, Maxaquin is not for use in children under 18 or pregnant women. The most frequent side effects reported in clinical studies include nausea, headache, dizziness and photosensitivity.
 However, unlike some quinolones, Maxaquin does not adversely interact with theophylline, a drug that is widely used for chronic bronchitis, asthma and other breathing disorders. In addition, as an oral, once-a-day medication, Maxaquin is more cost-effective than intravenous antibiotics, and offers patients a simpler treatment regimen.
 "Lack of patient compliance with the prescribed course of antibiotics, and often leads to treatment failure," notes Dr. Goode. "The ability to take a medication like Maxaquin just once a day clearly improves compliance and facilitates recovery.
 Headquartered in Skokie, Ill., Searle is a research-based company that develops, manufactures and markets pharmaceutical products worldwide. It is a wholly owned subsidiary of Monsanto Co.
 -0- 7/22/92
 /CONTACT: Jack Domeischel of Searle, 708-470-6720/
 (MTC) CO: Searle ST: Illinois IN: MTC SU:


LD -- NY106 -- 2131 07/22/92 17:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 22, 1992
Words:356
Previous Article:PHM CORPORATION RELEASES 1992 SECOND-QUARTER EARNINGS
Next Article:BRISTOL-MYERS SQUIBB ANNOUNCES COURT RULING
Topics:


Related Articles
ABBOTT LABORATORIES INTRODUCES NEW QUINOLONE ANTIBIOTIC
FIRST ONE-TABLET, ONCE-A-DAY QUINOLONE FOR ALL INDICATIONS ENTERS $5.1 BILLION U.S. ANTI-INFECTIVE MARKET
/C O R R E C T I O N -- Searle Market Approval/
SEARLE AND WYETH-AYERST TO CO-PROMOTE MAXAQUIN
SEARLE DONATES $500,000 OF MAXAQUIN (LOMEFLOXACIN HCL) TO RUSSIAN FOUNDATION
Bristol-Myers Squibb Acquires Novel Fluoroquinolone From Kyorin
Abbott Laboratories Announces Agreement with Wakunaga to Develop and Market Two Anti-Infective Compounds.
FDA Approves FACTIVE(R) (Gemifloxacin) for the Treatment Of Respiratory Tract Infections; Oral fluoroquinolone antibiotic kills the increasingly...
Daiichi Pharmaceutical of Japan Enters Into License With Pfizer For Potential New Anti-Infective; Daiichi compound shows significant in vitro...
MiddleBrook Announces Orange Book Listing of Moxatag Patents.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters